KIF22 in the Prognosis and Immune Biomarking of Pan-Cancer

Author:

Guo Xiuhong1,Cao Huayue2,Hu Mei3,Wu Yuening1,Li Jingxiang1ORCID

Affiliation:

1. Oral & Maxillofacial Reconstruction and Regeneration of Luzhou Key Laboratory, The Affiliated Stomatological Hospital of Southwest Medical University, Luzhou 646000, China

2. Department of Oral Implantology, The Affiliated Stomatological Hospital of Southwest Medical University, Luzhou 646000, China

3. Department of Ultrasound, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China

Abstract

KIF22, also known as kinesin-like DNA-binding protein (Kid), is a member of the Kinesin superfamily proteins (KIFs). Available evidence indicated that KIF22 was associated with cancer occurrence and development. However, the functions and underlying mechanisms of KIF22 in carcinogenesis and cancer progression remain largely unknown. In this study, we examined the expression profile and methylation status of KIF22 in different cancers, as well as its associations with prognosis, tumor stemness, genomic heterogeneity, immune evasion, immune infiltration, and therapeutic response in various tumor types. The results demonstrated that the expression level of KIF22 was higher in tumors than nontumor tissues and had strong relationships with prognosis, genomic heterogeneity, tumor stemness, neoantigen, ESTIMATE, and immune infiltration. KIF22 methylation status showed strong relationships with immunomodulators and chemokines. KIF22 had a significant relevance with drug susceptibility and could be a useful biomarker for forecasting survival probability and therapeutic reaction. Furthermore, KIF22 interaction and coexpression networks were mainly involved in cell division, cell cycle, DNA repair, and antigen processing and presentation. KIF22 could be used as a pan-cancer biomarker for clinical diagnosis, therapeutic schedule, prognosis, and cancer monitoring.

Funder

Sichuan Province Science and Technology Support Program

Publisher

Hindawi Limited

Subject

Immunology,General Medicine,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3